HARRISBURG – State Senator Daylin Leach (D-Montgomery/Delaware) on Wednesday announced that he has received applications to attend his conference on regulating medical marijuana from more than 280 people in over a dozen states. Applications from the public will continue to be accepted until June 16 at 8:30 a.m.
“Daylin Leach’s Medical Marijuana Regulatory-Palooza” will be held Friday, July 8 from 9 a.m. – 3 p.m. at Saint Joseph’s University in Philadelphia. The event is part of Leach’s plan to make recommendations to the Wolf Administration regarding implementation of Act 16, Leach’s medical marijuana protocol enacted on April 17.
The conference is free to attend, but space is limited, so those interested in attending must complete an online application at www.leachconference.com.
Leach looks forward to hosting a wide variety of stakeholders to enable vibrant and informed debate about the best way to regulate medical marijuana.
Specifically, he anticipates attendance by current and prospective patients, physicians, growers/processors, dispensers, industry attorneys, and investors.
State and local elected officials, as well as regulators from other medical marijuana states, are also expected to attend. The Wolf Administration intends to send representatives as well.
Shortly after the conference, Leach plans to oversee the drafting of a report offering recommendations for Pennsylvania’s permanent medical marijuana regulations. He hopes his report will serve as a nationwide model for medical marijuana regulations.
Leach also plans to submit comments on the temporary regulations that the Administration intends to publish in the coming weeks.
“Our work didn’t end with the enactment of my medical marijuana bill. As the Act 16 rulemaking process begins, we hope to gain input from the stakeholders who will have to live and work under the regulations we devise and experts from other states who have been through this process before.
“My goal is to produce a set of recommendations that will be helpful to the Wolf Administration’s regulators and to other states considering implementing or revising their own medical marijuana protocols.”